Carlsmed's preliminary Q4 revenue rises 61% to $15.2 mln
I'm PortAI, I can summarize articles.
Carlsmed's preliminary Q4 2025 revenue increased by 61% year-over-year to $15.2 million, with full-year revenue rising 86% to $50.5 million. The company added 101 new surgeon users, a 61% increase, contributing to this growth. Carlsmed anticipates further adoption of its aprevo platform in 2026 and aims for operational excellence. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $20.00, reflecting a potential upside of 57.6% from its recent closing price of $12.69.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments